Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netarsudil mesylate - Alcon

Drug Profile

Netarsudil mesylate - Alcon

Alternative Names: AR-13224; AR13324; Netarsudil mesylate; Netarsudil ophthalmic solution - Alcon; Rhokiinsa; Rhopressa; STN-1013900

Latest Information Update: 22 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Alcon; Cornea Research Foundation of America; Santen Pharmaceutical
  • Class Antiglaucomas; Eye disorder therapies; Isoquinolines; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Glaucoma

Highest Development Phases

  • Marketed Ocular hypertension; Open-angle glaucoma
  • Phase II Fuchs' endothelial dystrophy
  • No development reported Neurological disorders

Most Recent Events

  • 20 Mar 2023 GrayBug inc. has merged with CalciMedica to form CalciMedica
  • 28 Feb 2023 Launched for Ocular hypertension in Sweden (Ophthalmic) (Santen Pharmaceutical pipeline, July 2023)
  • 28 Feb 2023 Launched for Open-angle glaucoma in Sweden (Ophthalmic) (Santen Pharmaceutical pipeline, July 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top